New hope: drug may shield brain from CAR T-Cell therapy side effects
NCT ID NCT04205838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug anakinra could prevent severe brain inflammation (called ICANS) that sometimes happens after CAR T-cell therapy for certain types of lymphoma. The trial involved 23 adults whose lymphoma had returned or not responded to prior treatments. Researchers gave anakinra to calm the immune system and watched for serious brain side effects. The study was stopped early, but results help guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Davis Comprehensive Cancer Center
Davis, California, 95817, United States
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers